Desmoid tumors (also called aggressive fibromatoses) are sarcomas that affect fibrous tissues. They can be challenging to treat successfully. In this study, researchers are comparing the effectiveness of sorafenib with placebo in patients with desmoid tumors. Patients in the placebo group whose cancers continue to grow will be able to switch to sorafenib.
Sorafenib works by targeting several proteins involved in cancer growth. It is approved for treating cancers of the liver, kidney, and thyroid, but its use for treating desmoid tumors is considered investigational. It is taken orally (by mouth).
Patients will be randomly assigned to receive sorafenib (two-thirds of the patients) or a placebo (the remaining third).